Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Raafat Seifeldin"'
Publikováno v:
Diabetes Therapy
Introduction Patients with type 2 diabetes mellitus (T2DM) are clinically heterogeneous in terms of disease severity, treatment, and comorbidities, potentially resulting in differential diabetic nephropathy (DN) progression courses. In this explorato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f7e561ab59849e74a11b81f5586de83
https://doi.org/10.1007/s13300-018-0410-8
https://doi.org/10.1007/s13300-018-0410-8
Autor:
Raafat Seifeldin, Ernest H. Law, Ruixuan Jiang, Paresh Chaudhari, Anna P. Fang, Jing Zhao, Hongbo Yang, Eric Q. Wu, Zhou Zhou
Publikováno v:
Diabetes Therapy
Introduction Diabetic nephropathy (DN) is a progressive kidney disease resulting as a complication of diabetes mellitus. This study evaluated the disease progression and economic burden of DN among commercially insured patients with type 2 diabetes i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92ce92ad98dcdbc61828c537f241788e
http://europepmc.org/articles/PMC5446382
http://europepmc.org/articles/PMC5446382
Publikováno v:
Diabetes Research and Clinical Practice. 122:162-169
This study evaluates the association of pretreatment with oral antidiabetics (OADs) on clinical outcomes and health resource utilization among commercially insured type II diabetes mellitus (T2DM) patients in the United States.Using administrative da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5feffb8cc56a687d515a88e240534172
https://doi.org/10.1016/j.diabres.2016.10.020
https://doi.org/10.1016/j.diabres.2016.10.020
Autor:
M. Christopher Runken, Lawrence Rasouliyan, Thomas S. Marshall, Norman Zinner, Les Noe, Raafat Seifeldin
Publikováno v:
The American Journal of Geriatric Pharmacotherapy. 7:373-382
Background: Overactive bladder (OAB) is a common problem among the elderly and a financial burden to society. The prevalence of OAB increases with age and affects ≥25% of people aged ≥65 years. Objective: The goal of this exploratory subgroup ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a61dc281693927020bde8c02a6c3920
https://doi.org/10.1016/j.amjopharm.2009.11.004
https://doi.org/10.1016/j.amjopharm.2009.11.004
Autor:
Indrani Nandy, Scott Serels, Christine Laramée, Marc R. Toglia, Raafat Seifeldin, Mickey M. Karram, Masakazu Andoh, Sergio Forero-Schwanhaeuser
Publikováno v:
Postgraduate Medicine. 121:151-158
Overactive bladder (OAB) is a prevalent, chronic condition that can negatively affect health-related quality of life (HRQL). Treatment goals are to improve symptoms and HRQL. We assessed the efficacy of solifenacin in OAB patients using several patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a623cb7d2ca9a8e623a826d3a1e7151a
https://doi.org/10.3810/pgm.2009.09.2062
https://doi.org/10.3810/pgm.2009.09.2062
Autor:
Miriam G. Cisternas, Aimee J. Foreman, Kathleen C. Kobashi, Thomas S. Marshall, Raafat Seifeldin, M. Chris Runken
Publikováno v:
Current Medical Research and Opinion. 25:911-919
The goal of this study is to provide annual estimates for the treated prevalence and expenditures attributable to overactive bladder (OAB) in the elderly prior to Medicare Part D drug coverage.All Medicare claims were extracted for beneficiaries over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b735707d230544ad2be1717b6d47b08
https://doi.org/10.1185/03007990902791025
https://doi.org/10.1185/03007990902791025
Publikováno v:
Current Medical Research and Opinion. 24:1583-1591
Assess changes in resource utilization, work and activity impairment, and health utility among OAB patients continuing to have urgency symptoms with tolterodine ER 4 mg and willing to try solifenacin 5/10 mg.This was an open-label, non-comparative, f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b94abe485d6225f4902f799e421439b6
https://doi.org/10.1185/03007990802081766
https://doi.org/10.1185/03007990802081766
Publikováno v:
Clinical Therapeutics. 18:491-496
The effect of nifedipine on renal function in liver transplant recipients who were receiving tacrolimus was evaluated between January 1992 and January 1996. Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::749cd9e7534d3fb5a1e9e6b7be262e6e
https://doi.org/10.1016/s0149-2918(96)80030-0
https://doi.org/10.1016/s0149-2918(96)80030-0
Autor:
Raafat Seifeldin
Publikováno v:
Journal of Managed Care Pharmacy. 9:457-459
BACKGROUND: Although use of long-acting opioid analgesics has increased for chronic nonmalignant pain management, little is known about patient-reported utilization patterns. OBJECTIVE: To assess patient-reported utilization patterns of fentanyl tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ab36ab152f81fa8365d8ee2c1942ace
https://doi.org/10.18553/jmcp.2003.9.5.457
https://doi.org/10.18553/jmcp.2003.9.5.457
Cost-effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitis
Autor:
Charu, Taneja, Richard J, Antaya, Ariel, Berger, Thomas S, Marshall, Raafat, Seifeldin, Gerry, Oster
Publikováno v:
Journal of drugs in dermatology : JDD. 9(4)
Tacrolimus 0.1% and pimecrolimus 1.0% are used for short-term and noncontinuous treatment of atopic dermatitis (AD) in patients unresponsive to conventional therapies.To assess the cost-effectiveness of tacrolimus versus pimecrolimus in adults with A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1de81ebf56e2ef5878e45e97ade75eea
https://pubmed.ncbi.nlm.nih.gov/20514795
https://pubmed.ncbi.nlm.nih.gov/20514795